Biotech | May 05, 2022
Mediso acquires nuclear medicine supplier Bartec Technologies
In the UK, Bartec has been synonymous with Mediso products for 18 years, proof of a successful partnership
In the UK, Bartec has been synonymous with Mediso products for 18 years, proof of a successful partnership
The planned Phase 1 study is a double-blind, randomized, placebo-controlled dose-escalation study in healthy adult subjects and AD patients
Cysoni is a bionic device that paces the heart with real-time respiratory modulation
The respective expertise of Lonza and Integral Molecular will benefit drug developers in the assessment of the risk for off-target binding and activation
Peak Proteins has collaborated closely with Sygnature Discovery for several years and together the companies have supported a number of integrated drug discovery programmes
Under the terms of the partnership agreement, Comera will develop a differentiated formulation of an Intas product using Comera's innovative proprietary SQore formulation platform
The facility will support clinical development by securing supply that will address the critical demand in the gene therapy and vaccine markets
An RMAT confers eligibility for accelerated approval and priority review of biologics licensing applications (BLA)
GRC 54276 has shown tumour cell killing ability in preclinical studies as a single agent and as well in combination with checkpoint inhibitors, making it a high-priority target in immuno-oncology
Daewoong Pharmaceutical, HanAll Biopharma join Astellas Venture Management and other VCs in oversubscribed funding round to accelerate Turn Bio's preclinical advances in multiple therapeutic areas
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
